IT
ThePornDude
OnlyFans Finder
AI Whores 18+
#1 AI Nude Generator
Sex 'n Dolls
AI Girlfriend
#1 AI Porn Generator
Notizie e Aggiornamenti su Maat
Torna al ProfiloRicevi le ultime notizie, aggiornamenti e contenuti su Maat. Non perderti pettegolezzi o nuovi contenuti per adulti.
MaaT Pharma Announces Upcoming Pre-IND Meeting with the FDA and Advances MaaT034 Toward Clinical Development in Solid Tumors
MaaT Pharma has scheduled a Pre-IND CMC-focused meeting with the FDA in October 2026, the next regul...
MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in Hemato-Oncology
Tranche-based financing to support clinical development for the Company's late-stage assets in hemat...
MaaT Pharma to Present Four Abstracts at the 52nd European Bone Marrow Transplantation Annual Meeting and to Highlight Clinigen-Hosted Industry Symposium on acute GvHD Management
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a lea...
MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg® in acute Graft-versus Host Disease in Europe
In June 2025, the European Medicines Agency accepted for review the marketing authorization submissi...
MaaT Pharma Joins Microbiome Therapeutics Innovation Group
WASHINGTON, July 20, 2023 /PRNewswire/ -- The Microbiome Therapeutics Innovation Group (MTIG) today ...
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) iss...
MaaT wraps up cancer microbiome trial early to power into phase 2/3 this year
MaaT Pharma is racing its microbiome therapy into a late-phase cancer clinical trial. Rather than ta...
Maat hits its phase III endpoint in graft-vs.-host disease
Top-line data from Maat Pharma SA’s phase III study of MaaT-013, an enema microbiome ecosystem the...
Maat (Atenolol) Drug Price and Information
atenolol (Maat) (Maat) blocks beta-1 receptors, which are present on the heart. This prevents the ac...
Maat Pharma SA MAAT
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies...
MaaT Pharma Announces Positive Second Safety Interim Analysis from DSMB for Phase 2b PHOEBUS Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT
LYON, France, October 07, 2025--(BUSINESS WIRE)--Regulatory MaaT Pharma (EURONEXT: MAAT – the "Co...
MaaT's phase 3 GvHD trial hits goal, teeing up microbiome filing if cash crunch clears
A phase 3 trial of MaaT Pharma’s graft-versus-host disease (GvHD) drug candidate has hit its prima...
MaaT Pharma : Pioneering microbiome-driven therapy as new pillar in oncology
MaaT Pharma is charting new territory in oncology by positioning microbiome-driven therapy as a pote...
MaaT Pharma to Hold Annual General Meeting on June 16, 2026
LYON, France, May 11, 2026--(BUSINESS WIRE)--Regulatory MaaT Pharma (EURONEXT: MAAT – the "Compan...
MaaT Pharma Announces Plan to Request Re-Examination Following Negative CHMP Opinion for MaaT013 for the treatment of acute Graft-versus-Host Disease
LYON, France, June 26, 2026--(BUSINESS WIRE)--Regulatory MaaT Pharma (EURONEXT: MAAT – the "Compa...
MaaT Pharma Presents Preclinical Data at AACR Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034
LYON, France, April 28, 2025--(BUSINESS WIRE)--Regulatory MaaT Pharma (EURONEXT: MAAT – the "Comp...
MaaT microbiota drug shows survival advantage in GvHD
MaaT Pharma’s quest to bring a microbiota-based therapy to market has moved a step forward with ne...
MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2025
Positive results from Phase 3 trial for MaaT013 in acute Graft-versus-Host disease (aGvHD); topline ...
MaaT Pharma Announces the Presentation of Positive Data with Its Lead Microbiome Biotherapeutic in Intestinal-Predominant Acute Graft-versus-Host-Disease at the ASH 2019 Annual ...
LYON, France--(BUSINESS WIRE)--MaaT Pharma announced today that leading hemato-oncological experts p...
MaaT Pharma Provides Business Objectives and Expected Milestones for 2022
Important clinical milestones are expected in 2022 in the Company’s hemato-oncology and immuno-onc...
MaaT Pharma Announces Initiation of Coverage of its Stock by Stifel with a Buy Rating and a Target Price of EUR 16
LYON, France, June 25, 2024--(BUSINESS WIRE)--Regulatory MaaT Pharma (EURONEXT: MAAT – the "Compa...
MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2026
In May 2026, the Company was informed of a “negative trend” opinion on its Marketing Authorizati...
MaaT Pharma reports safety interim analysis from trial of microbiome therapy
French biotechnology company MaaT Pharma has reported positive results from an interim safety analys...
MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in ...
IMMUNOLIFE, a Phase 2 randomized exploratory study, will evaluate the potential of MaaT033 in combin...
MaaT Pharma, Leader in Development of Microbiome-Based Therapies in Oncology, Awarded Government Funding for Clinical Development of MaaT033 as part of the France 2030 Plan
MaaT Pharma secures important funding in line with one of the goals under the Health Innovation 2030...
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
(1) In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on th...
MaaT Pharma Presents the Results of its Annual General Meeting and Provides a Statement on its Half-Year Liquidity Contract
MaaT Pharma Presents the Results of its Annual General Meeting and Provides a Statement on its Half-...
AACR 2025: MaaT Pharma, the gut microbiome, and immuno-oncology
Lyon, France-based late-stage clinical biotech MaaT Pharma has presented new preclinical data for Ma...
MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2024
Positive efficacy and safety data of MaaT013 in aGvHD in the Early Access Program presented at the E...
A simple memory technique helped chemotherapy patients stay mentally sharp during treatment
Chemotherapy patients who learned structured memory and attention strategies through a workbook-base...